Champions Oncology (FRA:2I3) Cyclically Adjusted FCF per Share: €-0.07 (As of Jan. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2I3 Champions Oncology Inc FRA:2I3
64 GF Score
Price €5.20
GF Value €5.45
! 2 Warning Signs
View Full Analysis

What is Champions Oncology Cyclically Adjusted FCF per Share?

Champions Oncology FRA:2I3 +6.12% 64 Cyclically Adjusted FCF per Share is €-0.07 as of Jan. 2026. GuruFocus rates FRA:2I3 with a GF Score™ of 64/100 and a GF Value™ of €5.45. The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Champions Oncology's adjusted free cash flow per share for the three months ended in Jan. 2026 was €-0.084. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.07 for the trailing ten years ended in Jan. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 32.80% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 22.00% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 9.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Champions Oncology was 32.80% per year. The lowest was -37.50% per year. And the median was -4.20% per year.

As of today (2026-07-20), Champions Oncology's current stock price is €5.20. Champions Oncology's Cyclically Adjusted FCF per Share for the quarter that ended in Jan. 2026 was €-0.07. Champions Oncology's Cyclically Adjusted Price-to-FCF of today is .


Champions Oncology  (FRA:2I3) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Champions Oncology Cyclically Adjusted FCF per Share Related Terms


Champions Oncology Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Champions Oncology's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Champions Oncology Cyclically Adjusted FCF per Share Chart

Champions Oncology Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.61 -0.54 -0.40 -0.39 -0.15

Champions Oncology Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.22 -0.15 -0.10 -0.08 -0.07

FRA:2I3 vs SEER, RLYB, FBIO: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Champions Oncology's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Champions Oncology Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Champions Oncology's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Champions Oncology's Cyclically Adjusted Price-to-FCF falls into.


FRA:2I3
64GF Score
Champions Oncology Inc FRA:2I3
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Champions Oncology Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Champions Oncology's adjusted Free Cash Flow per Share data for the three months ended in Jan. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jan. 2026 (Change)*Current CPI (Jan. 2026)
=-0.084/325.2520*325.2520
=-0.084

Current CPI (Jan. 2026) = 325.2520.

Champions Oncology Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201604 -0.071 239.261 -0.097
201607 -0.226 240.628 -0.305
201610 -0.011 241.729 -0.015
201701 -0.071 242.839 -0.095
201704 -0.014 244.524 -0.019
201707 -0.226 244.786 -0.300
201710 0.018 246.663 0.024
201801 0.028 247.867 0.037
201804 -0.015 250.546 -0.019
201807 0.008 252.006 0.010
201810 -0.013 252.885 -0.017
201901 0.076 251.712 0.098
201904 0.007 255.548 0.009
201907 -0.079 256.571 -0.100
201910 0.041 257.346 0.052
202001 0.007 257.971 0.009
202004 0.074 256.389 0.094
202007 -0.088 259.101 -0.110
202010 0.021 260.388 0.026
202101 -0.060 261.582 -0.075
202104 -0.160 267.054 -0.195
202107 -0.044 273.003 -0.052
202110 0.039 276.589 0.046
202201 0.237 281.148 0.274
202204 0.019 289.109 0.021
202207 -0.069 296.276 -0.076
202210 0.201 298.012 0.219
202301 0.056 299.170 0.061
202304 -0.098 303.363 -0.105
202307 -0.312 305.691 -0.332
202310 0.036 307.671 0.038
202401 -0.068 308.417 -0.072
202404 -0.124 313.548 -0.129
202407 0.020 314.540 0.021
202410 -0.019 315.664 -0.020
202501 0.033 317.671 0.034
202504 0.417 320.795 0.423
202507 0.034 323.048 0.034
202510 -0.117 0.000
202601 -0.084 325.252 -0.084

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-0.07 mean?
Champions Oncology (FRA:2I3) has a Cyclically Adjusted FCF per Share of €-0.07 as of Jan. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Champions Oncology and its competitors.
Is Champions Oncology's Cyclically Adjusted FCF per Share too high?
Champions Oncology's current Cyclically Adjusted FCF per Share is €-0.07. Overall, Champions Oncology has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Champions Oncology's Cyclically Adjusted FCF per Share compare to SEER and RLYB?
Champions Oncology's Cyclically Adjusted FCF per Share of €-0.07 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Champions Oncology and its competitors. Champions Oncology's current Cyclically Adjusted FCF per Share is €-0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Champions Oncology stock overvalued right now?
Champions Oncology (FRA:2I3) has a current Cyclically Adjusted FCF per Share of €-0.07. The stock's GF Value™ is €5.45, compared to a current price of €5.20 — trading 4.6% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €-0.07. Champions Oncology's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Champions Oncology (FRA:2I3), the current Cyclically Adjusted FCF per Share is €-0.07 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Champions Oncology (FRA:2I3) Overvalued in 2026?

Based on GuruFocus' analysis, Champions Oncology stock appears to be undervalued. The current stock price of €5.20 is trading 4.6% below its estimated GF Value™ of €5.45.

Key valuation signals for FRA:2I3:

  • Cyclically Adjusted FCF per Share: €-0.07
  • GF Value™: €5.45 vs. price of €5.20 (4.6% below fair value)
  • GF Score™: 64/100 with 2 warning signs

No single metric tells the full story. See the FRA:2I3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Champions Oncology Business Description

Other Exchanges CSBR:USA
Address One University Plaza, Suite 307, Hackensack, NJ, USA, 07601
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
64GF Score

Get the complete analysis for FRA:2I3

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.20
Price
€5.45
GF Value